Acute Mountain Sickness and High Altitude Cerebral Oedema

Bärtsch, Peter; Bailey, Damian Miles

doi:10.1007/978-1-4614-8772-2_20

Cited by 22 publications

(30 citation statements)

References 178 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At altitudes between 2500 and 3000 m, the prevalence of acute mountain sickness is 10 -30%, depending on the population, and at altitudes of 4000 -4500 m the prevalence rises to 40 -60%, 17 which is consistent with the results of the present study. Some individuals appear to be more susceptible to 1 This fact has led researchers to exert substantial efforts towards explaining the differences in susceptibility and creating methods that predict the risks of acute mountain sickness development.…”

Section: Discussionsupporting

confidence: 93%

Associations between Vascular Endothelial Growth Factor Gene Polymorphisms and Susceptibility to Acute Mountain Sickness

et al. 2012

View full text Add to dashboard Cite

OBJECTIVE: This study investigated associations between polymorphisms in the vascular endothelial growth factor (VEGF) gene and susceptibility to acute mountain sickness. METHODS: Two hundred Han Chinese soldiers who developed acute mountain sickness after rapidly ascending to an altitude of < 3600 m and 200 control soldiers (who did not develop the condition) were enrolled in the study. Twelve single nucleotide polymorphisms (SNPs) of the VEGF gene were genotyped in all the study participants. Plasma VEGF concentrations were measured by enzymelinked immunosorbent assay in 40 subjects with acute mountain sickness and 40 controls before and after exposure to high altitude. RESULTS: The frequencies of the rs3025039 genotype and allele were significantly different between the groups. Two SNPs, rs3025039 (which involves a C→T allele variation at position 936 in the 3′ untranslated region) and rs3025030 (which involves a G→C allele variation in the intronic sequence), were associated with a decreased risk of acute mountain sickness. CONCLUSION: The SNPs rs3025039 and rs3025030 of the VEGF gene may be associated with a decreased risk of acute mountain sickness development.

show abstract

Section: Discussionsupporting

confidence: 93%

Associations between Vascular Endothelial Growth Factor Gene Polymorphisms and Susceptibility to Acute Mountain Sickness

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The symptoms are usually most pronounced after the first night spent at a new altitude and resolve spontaneously when appropriate measures are taken [1]. The leading symptom is headache, which is required for the diagnosis of AMS by the most frequently used scoring system [2].…”

Section: Ams and Hacementioning

confidence: 99%

“…A lower ventilatory drive in hypoxia [7,13], impaired gas exchange due to interstitial pulmonary oedema [10] and fluid retention [7] or increased metabolism [1] may contribute to slightly more pronounced hypoxaemia in AMS.…”

Section: Hypoxaemiamentioning

confidence: 99%

Acute high-altitude sickness

2017

Self Cite

View full text Add to dashboard Cite

At any point 1-5 days following ascent to altitudes ⩾2500 m, individuals are at risk of developing one of three forms of acute altitude illness: acute mountain sickness, a syndrome of nonspecific symptoms including headache, lassitude, dizziness and nausea; high-altitude cerebral oedema, a potentially fatal illness characterised by ataxia, decreased consciousness and characteristic changes on magnetic resonance imaging; and high-altitude pulmonary oedema, a noncardiogenic form of pulmonary oedema resulting from excessive hypoxic pulmonary vasoconstriction which can be fatal if not recognised and treated promptly. This review provides detailed information about each of these important clinical entities. After reviewing the clinical features, epidemiology and current understanding of the pathophysiology of each disorder, we describe the current pharmacological and nonpharmacological approaches to the prevention and treatment of these diseases.

show abstract

“…Patient history is therefore a key component in diagnosis as HAPE is always preceded by rapid high altitude ascent [2]. Nevertheless, other symptoms need to be clinically correlated.…”

Section: Pathophysiology Of Hapementioning

confidence: 99%

“…Further, it has been classified in three strata: high altitude, 1500-3500 m, very high altitude 3500-5500 m and extreme altitude >5500 m [1]. Rapid ascent to the altitudes above 2500 m is associated with several diseases like acute mountain sickness (AMS), high altitude cerebral edema (HACE), Monge disease (Chronic mountain sickness) and high altitude pulmonary edema (HAPE) [2]. Although initial phases of many of these diseases are reversible and have successfully been cured, prolonged persistence can prove lethal.…”

Section: Introductionmentioning

confidence: 99%

High Altitude Pulmonary Edema: An Update on Omics Data and Redefining Susceptibility

Gangwar¹

2015

J Proteomics Bioinform

View full text Add to dashboard Cite

Acute Mountain Sickness and High Altitude Cerebral Oedema

Cited by 22 publications

References 178 publications

Associations between Vascular Endothelial Growth Factor Gene Polymorphisms and Susceptibility to Acute Mountain Sickness

Associations between Vascular Endothelial Growth Factor Gene Polymorphisms and Susceptibility to Acute Mountain Sickness

Acute high-altitude sickness

High Altitude Pulmonary Edema: An Update on Omics Data and Redefining Susceptibility

Contact Info

Product

Resources

About